Literature DB >> 29019797

The promise of mesenchymal stem cell therapy for acute respiratory distress syndrome.

Ben Antebi1, Arezoo Mohammadipoor, Andriy I Batchinsky, Leopoldo C Cancio.   

Abstract

This review describes the current state of the science on mesenchymal stem cell (MSC) treatment for acute lung injury (ALI). The general characteristics, regenerative potential, and mechanism of action of MSCs are first presented. Next, particular emphasis is placed on the application of MSCs for the treatment of acute respiratory distress syndrome (ARDS) in preclinical and clinical studies. Finally, we discuss current challenges and future directions in the field presented from a clinician-researcher perspective. The objective of this work is to provide the readership with a current review of the literature discussing the hurdles and overall promise of MSCs as therapeutic interventions for the treatment of ARDS.

Entities:  

Mesh:

Year:  2018        PMID: 29019797     DOI: 10.1097/TA.0000000000001713

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  19 in total

Review 1.  Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials.

Authors:  Hong-Long Ji; Cong Liu; Run-Zhen Zhao
Journal:  World J Stem Cells       Date:  2020-06-26       Impact factor: 5.326

Review 2.  Therapeutic potential of products derived from mesenchymal stem/stromal cells in pulmonary disease.

Authors:  Arezoo Mohammadipoor; Ben Antebi; Andriy I Batchinsky; Leopoldo C Cancio
Journal:  Respir Res       Date:  2018-11-09

3.  Preconditioning in an Inflammatory Milieu Augments the Immunotherapeutic Function of Mesenchymal Stromal Cells.

Authors:  Luis A Rodriguez; Arezoo Mohammadipoor; Lucero Alvarado; Robin M Kamucheka; Amber M Asher; Leopoldo C Cancio; Ben Antebi
Journal:  Cells       Date:  2019-05-15       Impact factor: 6.600

4.  Cryopreserved mesenchymal stem cells regain functional potency following a 24-h acclimation period.

Authors:  Ben Antebi; Amber M Asher; Luis A Rodriguez; Robbie K Moore; Arezoo Mohammadipoor; Leopoldo C Cancio
Journal:  J Transl Med       Date:  2019-08-29       Impact factor: 5.531

5.  Mesenchymal Stem Cells Reconditioned in Their Own Serum Exhibit Augmented Therapeutic Properties in the Setting of Acute Respiratory Distress Syndrome.

Authors:  Amy L Xu; Luis A Rodriguez; Kerfoot P Walker; Arezoo Mohammadipoor; Robin M Kamucheka; Leopoldo C Cancio; Andriy I Batchinsky; Ben Antebi
Journal:  Stem Cells Transl Med       Date:  2019-06-20       Impact factor: 6.940

Review 6.  Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.

Authors:  Christopher J Rogers; Robert J Harman; Bruce A Bunnell; Martin A Schreiber; Charlie Xiang; Fu-Sheng Wang; Antonio F Santidrian; Boris R Minev
Journal:  J Transl Med       Date:  2020-05-18       Impact factor: 5.531

Review 7.  Mesenchymal stem cells: current clinical progress in ARDS and COVID-19.

Authors:  Kun Xiao; Fei Hou; Xiuyu Huang; Binbin Li; Zhi Rong Qian; Lixin Xie
Journal:  Stem Cell Res Ther       Date:  2020-07-22       Impact factor: 6.832

8.  The effect of acute respiratory distress syndrome on bone marrow-derived mesenchymal stem cells.

Authors:  Ben Antebi; Kerfoot P Walker; Arezoo Mohammadipoor; Luis A Rodriguez; Robbie K Montgomery; Andriy I Batchinsky; Leopoldo C Cancio
Journal:  Stem Cell Res Ther       Date:  2018-09-26       Impact factor: 6.832

9.  Short-term physiological hypoxia potentiates the therapeutic function of mesenchymal stem cells.

Authors:  Ben Antebi; Luis A Rodriguez; Kerfoot P Walker; Amber M Asher; Robin M Kamucheka; Lucero Alvarado; Arezoo Mohammadipoor; Leopoldo C Cancio
Journal:  Stem Cell Res Ther       Date:  2018-10-11       Impact factor: 6.832

Review 10.  Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.

Authors:  Hua Qin; Andong Zhao
Journal:  Protein Cell       Date:  2020-06-09       Impact factor: 14.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.